Business Context and Reporting Period
This Form 8-K Current Report was filed by Denali Therapeutics Inc. on March 14, 2022. The filing reports significant changes in executive leadership and board composition effective May 1, 2022.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Appointment of CFO: Alexander Schuth, M.D., currently the Chief Operating Officer and Secretary, was appointed Chief Financial Officer, effective May 1, 2022. He will hold the combined title of Chief Operating and Financial Officer.
- Transition of Former CFO: Steve Krognes will cease serving as Chief Financial Officer on April 30, 2022, and will join the Board of Directors as a Class III director effective May 1, 2022.
- Compensation Adjustments: Dr. Schuth's compensation arrangements remain unchanged. Mr. Krognes will receive annual cash compensation of $45,000 for his board service, payable quarterly. He waived his right to initial equity awards and is ineligible for annual equity awards at the 2022 annual meeting due to tenure requirements.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, outlook, or specific risk factors. Management commentary is limited to the announcement of the leadership transition and the attached press release.
Investor Verification Checklist
- Verify the effective date of the CFO transition (May 1, 2022) and the interim period coverage.
- Confirm Dr. Schuth's background and experience in finance and biopharmaceuticals.
- Review the attached press release (Exhibit 99.1) for additional context on the strategic rationale for the leadership change.
- Monitor future filings for any changes to Dr. Schuth's compensation or Mr. Krognes' board tenure.